Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFa agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease
LAUSANNE, Switzerland, Aug 23, 2022 – (ACN Newswire) – Oculis S.A., (‘Oculis’) a global ophthalmology…